To view a video summarising Evolution’s technology and current activities, please click here
Phage therapy:
the natural answer
to antibiotic resistance
the natural answer
to antibiotic resistance
Evolution Biotechnologies Incorporated is a US company, working to expand biological control from its successful applications elsewhere, bringing this “green” technology to the control of medically important targets. The activities of the company build on previous successes with phage therapy, the use of naturally-occurring and highly specific viruses of bacteria, using these as a new approach to target antibiotic-resistant bacterial infections.
Antibiotics have saved countless lives, but antimicrobial resistance is now a critically important and worldwide problem. It has been stated that such resistance is bringing “an end to modern medicine as we know it” and that unless new approaches are developed, routine surgery may become impossible, and routine infections will kill. New approaches are needed, and are needed urgently.
Every bacterial species has its own predators; viruses (bacteriophages) that specifically target it. If used correctly, these can destroy bacteria in a highly specific and sustainable manner, amplifying up from tiny initial doses with minimal side effects. This approach, known as phage therapy, is considered to be a highly promising way to counter antimicrobial resistance, bringing new and effective treatments to the clinic.
Operating from its base in Texas, the company is addressing the crisis of antimicrobial resistance using the highly promising approach of phage therapy. This will initially target Pseudomonas aeruginosa infections in companion animals in order to provide sustainable income to support later entry into human medicine, focused on the same bacterial target. Projected markets for its initial target in veterinary and human applications exceed $1 billion per annum.
